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A novel MTTT mutation m.15933G > A
revealed in analysis of mitochondrial DNA
in patients with suspected mitochondrial
disease
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Abstract
Background: Mitochondrial diseases present with variable multi-organ symptoms. Common disease-causing
mutations in mitochondrial DNA (mtDNA) are regularly screened in diagnostic work-up, but novel mutations may
remain unnoticed.
Methods: Patients (N = 66) with a clinical suspicion of mitochondrial disease were screened for their mtDNA coding
region using conformation sensitive gel electrophoresis and sequencing. Long-PCR was used to detect deletions
followed by POLG1 sequencing in patients with multiple deletions.
Results: We discovered three novel mtDNA variants that included m.8743G > C, m.11322A > G and m.15933G > A.
The novel MTTT variant m.15933G > A is suggested to be pathogenic. Analysis revealed also multiple mtDNA
deletions in two patients and five nonsynonymous variants that were putatively pathogenic according to in-silico
prediction algorithms. In addition, a rare haplogroup H associated m.7585_7586insT variant was discovered.
Conclusions: Among patients with a suspected mitochondrial disease, a novel MTTT variant m.15933G > A was
discovered and is suggested to be pathogenic. In addition, several putatively pathogenic nonsynonymous variants
and rare variants were found. These findings highlight the importance of coding region mtDNA screening among
patients with clinical features suggesting a mitochondrial disease, but who lack the common mitochondrial disease
mutations.
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Background
More than 200 pathogenic point mutations and large-
scale rearrangements have been described in mitochon-
drial DNA (mtDNA) [1]. Some of the most common
mitochondrial diseases caused by mutations in mtDNA
are Kearns-Sayre syndrome, Leber’s hereditary optic
neuropathy, myoclonic epilepsy with ragged red fibers
syndrome, MELAS syndrome (mitochondrial encephalo-
myopathy, lactic acidosis with stroke-like episodes) and
the syndrome of neuropathy, ataxia and retinitis pig-
mentosa (NARP). The prevalence of mitochondrial dis-
eases caused by mtDNA mutations has been calculated
to be 1:5000 in the adult population [1, 2] and the total
prevalence rises up to 1:4300, when disorders caused by
mutations in nuclear-encoded genes contributing to
mitochondrial functions are included [3].
Screening of established pathogenic mtDNA and nDNA
mutations is straightforward, but detection of novel or
rare mtDNA mutations is more tedious. Such mutations
may remain unnoticed, unless the entire mtDNA coding
region is sequenced after excluding known mitochondrial
disease mutations. However, conventional sequencing
methods do not detect large mtDNA deletions, nor are
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they good in recognizing extremes of mtDNA hetero-
plasmy. It is also imperative to be able to analyse the
pathogenic potential of novel or rare mtDNA mutations
and to determine their frequency in the population [4], as
mtDNA is highly variable by nature. There is also emer-
ging evidence suggesting that polymorphic variation can
influence disease phenotype and raise the risk for develop-
ing a mitochondrial disorder [5–9]. Furthermore, mtDNA
variants have been suggested to increase the risk of com-
mon neurodegenerative diseases, such as Alzheimer’s and
Parkinson’s disease [10–13]. In this sense, the Finnish
population is ideal for detecting underlying genetic risk
factors, as it is considered to be a genetically isolated,
homogenous population.
In the present study, we screened the mtDNA coding
region of 66 patients with a clinical suspicion of a mito-
chondrial disease. Our aim was to determine mtDNA
sequence for rare mtDNA variants and to assess if they
were pathogenic mutations or polymorphic risk factors.
Conformation sensitive gel electrophoresis (CSGE) and
sequencing were used to determine the mtDNA coding
region of the patients and long-PCR was used to detect
multiple mtDNA deletions. Polymerase γ gene (POLG1)
was sequenced in multiple deletions patients.
Methods
Patients and population controls
Finnish patients (N = 66) with a clinically suspected
mitochondrial disease were examined. Muscle samples
(N = 21), blood samples (N = 36) or both (N = 9) were
obtained. Common symptoms among selected patients
included exercise intolerance, myopathy, encephalomy-
opathy, cardiomyopathy, diabetes mellitus, sensorineural
hearing impairment and progressive external ophthal-
moplegia. The patients consisted of sporadic cases or
cases with similar symptoms in maternal relatives. The
ethics committee of the University of Oulu has approved
the study protocol and all patients gave a written in-
formed consent for participation in the study.
Anonymous healthy blood donors (N = 480) were used
as population controls. It was required that the donor
and his or her mother were born in the same region,
and that the donor did not report neurological ailments,
diabetes or sensorineural hearing impairment in the
family. MtDNA haplogroups have been determined in
all of the 480 controls [14], the hypervariable segment I
(HVSI) in the D-loop has been sequenced in 403 con-
trols [15] and the entire mtDNA sequence has been de-
termined in 192 controls [14]. The ethics committee of
the Finnish Red Cross has approved the study protocol.
Molecular methods
Total DNA was extracted from blood by using the
QIAmp Blood Kit (Qiagen, Hilden, Germany). Total
DNA from muscle samples was extracted by using Wiz-
ard® Genomic DNA purification kit (Promega, Madison,
WI, U.S.A.) and standard tissue DNA extraction method
using phenol and chloroform. MtDNA haplogroups were
determined by restriction fragment analysis [16].
Forty-one samples were analysed by using conform-
ation sensitive gel electrophoresis (CSGE) as previously
described [17, 18]. The mtDNA coding region, nucleo-
tides m.577-m.16090, was amplified in 63 partially over-
lapping fragments. Each amplified fragment was mixed
with the corresponding fragment amplified on a control
template with a known sequence. Heteroduplex forma-
tion was also allowed to occur autogenously enabling
the detection of heteroplasmic mutations. Heterodu-
plexes that differed in mobility in CSGE were sequenced
(ABI PRISM ™ 377 Sequencer using DYEnamic ET
Terminator Cycle Sequencing Kit; Amersham Pharmacia
Biotech Inc., Buckinghamshire, U.K.) after purification
with exonuclease I and shrimp alkaline phosphatase
[19]. The primers used for sequencing were the same as
those used for the amplification of the 63 CSGE frag-
ments. Twenty-five samples were sequenced directly for
their entire mtDNA. The mtDNA was first amplified in
11 fragments followed by sequencing using primers that
were used for the amplification of mtDNA fragments.
Muscle DNA samples (N = 30) were examined for
multiple mtDNA deletions by using long-PCR (Phusion
expand XL-PCR, Boehringer Mannheim, Mannheim,
Germany) as described previously [20]. Certain POLG1
mutations are fairly common in the Finnish population
and, hence, the entire POLG1 gene (NCBI Reference Se-
quence: NM_002693) was sequenced in the two samples
that were found to harbour multiple mtDNA deletions.
Next-generation sequencing would have provided an
effective tool for mtDNA analysis and heteroplasmy
detection but, unfortunately, this method was beyond
our resources at the time of investigation.
Analysis of mtDNA variants
Sequences were compared to the revised Cambridge ref-
erence sequence [GenBank: NC_012920] [21] and to
mtDNA sequences available in the Mitomap database
http://www.mitomap.org [22]. Variants were considered
rare if they occurred ≤ 10 times in the Mitomap database
among 32,059 mtDNA sequences. Novel substitutions
were confirmed by RFLP or by sequencing in both direc-
tions at least twice from different PCR products. The
possibility of m.15933G > A being an artefact caused by
nuclear mitochondrial DNA was examined by amplifying
total mtDNA of patient 41 with long-PCR (XL-PCR)
Expand Long Template PCR system kit (Boehringer
Mannheim) as described previously [20] and by subse-
quently sequencing the mutation site with a forward pri-
mer at m.15714 and a reverse primer at m.16090.
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Conservation of nucleotides among species was evalu-
ated using Mamit tRNA: Compilation of Mammalian
mitochondrial tRNA genes http://mamit-tRNA.u-stra
sbg.fr [23] in the case of tRNA genes and GiiB-JST
mtSAP evaluation http://mtsnp.tmig.or.jp/cgi-bin/mts
np/specAlign/ctrlSpecAlignE.cgi in the case of structural
mtDNA genes [24]. The pathogenicity of m.15933G > A
was assessed by means of a multifactorial probability-
based classification method PON-mt-tRNA that predicts
the pathogenicity of single nucleotide substitutions in
human mitochondrial tRNAs [25].
Analysis of nonsynonymous mtDNA mutations
Nonsynonymous mtDNA mutations were analysed for
their pathogenic potential by using PolyPhen-2 version
2.2.2 [26] http://genetics.bwh.harvard.edu/pph2/, SIFT B
Link [27] http://sift.jcvi.org/www/SIFT_BLink_submit.
html, PMut [28, 29] http://mmb2.pcb.ub.es/PMut/ and
SNAP [30] http://rostlab.org/services/snap/ algorithms.
Pathogenicity classes were ascertained according to the
guidelines suggested by Wallis et al. 2013 and Claustres
et al. 2014 [31, 32].
PolyPhen-2 calculates a naïve Bayes posterior probabil-
ity for each mutation to assess its damaging potential.
Mutations are then classified as benign if the probability
is less than 50%, possibly damaging if the probability is
greater than 50% and probably damaging if the probabil-
ity is greater than 90%.
SIFT BLink and PMut algorithms are based on sequence
homology. These algorithms assume that functionally im-
portant protein sequences are conserved in evolution,
whereas diverse positions are unimportant to protein
function. SIFT scores for nonsynonymous mutations
range between 0–1 and scores of ≤ 0.05 are considered to
be deleterious. PMut also uses information on sequence
conservation and neural networks to predict whether a
variant is benign or pathogenic. PMut provides a reliability
index ranging from 0 (most unreliable) to 9 (most reli-
able). SNAP predicts functional effect by using conserva-
tion and functional information of proteins, such as
secondary structure and solvent accessibility. A variant is
assigned either neutral or non-neutral. A reliability index
(0 being the most reliable prediction and 7 being the most
unreliable) and an accuracy percentage is also provided.
Exact test of population differentiation as implemented
in Arlequin 3.5 was used to compare frequencies of
mtDNA haplogroups between cases and controls [33].
Phylogenetic networks of mtDNA sequences were
constructed on the basis of median algorithm [34].
Results
MtDNA sequence variation and novel mutations
The frequency of mtDNA haplogroups did not differ be-
tween the 66 patients with suspected mitochondrial
disease and the controls. Three novel homoplasmic vari-
ants, m.8743G > C, m.11322A > G and m.15933G > A
were discovered (Fig. 1). The m.11322A > G variant (p.
N188S, MTND4) was found in two siblings, one (patient
21) with hypertrophic cardiomyopathy, chronic atrial fib-
rillation and sick sinus syndrome and the other (patient
22) with ptosis, restricted eye movements and exercise
intolerance. The nucleotide position m.11322 is not
notably conserved among 60 species which were investi-
gated with GiiB-JST mtSAP evaluation http://mtsnp.tmi-
g.or.jp/cgi-bin/mtsnp/specAlign/ctrlSpecAlignE.cgi [24].
The other two novel variants m.8743G > C (p.V73L,
MTATP6) and m.15933G > A in MTTT were found in
the muscle and blood of patient 41. The nucleotide at
position m.8743 is not particularly conserved, whereas
m.15933G is a highly conserved (Table 1, Fig. 2). The
m.15933G > A mutation was predicted to be pathogenic
with a probability score of 0.92 by PON-mt-tRNA
method. Sequencing revealed that the m.15933G > A
variant was present in an amplicon obtained in a long-
range PCR amplification covering the whole mtDNA of
patient 41.
Patient 41 is a 51-year old woman. Her athletic achieve-
ments did not match those of the other girls at school. In
adulthood she has had poor muscle fitness, and exercise-
induced muscle weakness and myalgia. In addition, she
has mild dysphagia and choking tendency. In her forties a
nonsymmetrical ptosis developed and her right eye was
operated at age 47 years. Psoriatic skin rash developed at
age 49 years. Clinical neurological examination and blood
lactate were normal. Muscle histology revealed ragged red
fibers (RRF) and COX-negative fibers.
In addition, three other variants were considered rare
occurring ≤10 times in the Mitomap database of 32,059
sequences. The rare insertion m.7585_7586insT (N = 4
in Mitomap database) between MTTD and MTCO2 was
found in patient 16. This insertion adds a thymidine
between the last nucleotide of MTTD and the first
nucleotide of MTCO2 (Fig. 2). Cloning revealed that the
insertion was present in all 100 clones investigated
suggesting that the mutation in muscle mtDNA is
homoplasmic with high probability. The other rare vari-
ants were m.4924G > C (p. S152T, MTND2) and
m.7706G > A (p. A41T, MTCO2). The frequency of the
rare nonsynonymous variants among the 66 patients did
not differ from that in 89 haplogroup-matched controls
drawn from the population [14].
In-silico analysis of nonsynonymous variants
All the nonsynonymous mtDNA variants (N = 47) dis-
covered in the 66 patients were analysed for their patho-
genic potential using PolyPhen-2, SIFT BLink, PMut and
SNAP algorithms. Five of the mutations were predicted
to be deleterious by at least three of the algorithms
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(Table 2). The highest probability in favour of a patho-
genic effect was obtained for m.8616G > T (p. L30F,
MTATP6). With the exception of m.5095 T > C (p.I209T,
MTND2) and m.14180 T > C (p. Y165C, MTND6), the
three other variants predicted to be deleterious have
previously been reported to be haplogroup-associated.
Multiple mtDNA deletions
Muscle samples from 30 patients were analysed for mul-
tiple mtDNA deletions. Patients 59 and 22 (Fig. 1) were
found to harbour multiple deletions. Patient 59 suffered
from bilateral progressive external ophthalmoplegia, dip-
lopia, ptosis and mild exercise intolerance. His muscle
histology revealed numerous RRFs and COX-negative
muscle fibers. He harboured a heterozygous p.R722H
allele in POLG1, but no potentially pathogenic mtDNA
mutations.
Patient 22 harboured multiple mtDNA deletions and
the novel m.11322A > G variant (p. N188S, MTND4),
but not POLG1 mutations. Her daughter had increased
Fig. 1 Phylogenetic network of the mtDNA coding region in 66 patients with suspected mitochondrial disease. Patients are identified by
numbers inside the nodes. Outgroup = an African sequence (GenBank: AF346980); CRS = the revised Cambridge Reference Sequence (GenBank:
NC_012920). Unless marked otherwise, mtDNA variants are transitions. Superscript text indicates transversions. Insertions are marked with
superscript (i), back mutations (@) and heteroplasmic mutations are marked with an asterisk (*). Underlined red font, variants predicted to be
likely pathogenic, blue font novel mutations, green font rare mutations, purple font multiple mtDNA deletions and POLG1 mutations
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lactate in blood. No mtDNA deletions were detected in
her brother (patient 21).
Discussion
We discovered three previously unreported mtDNA vari-
ants, three rare variants and a total of 47 nonsynonymous
variants among 66 patients with suspected mitochondrial
disease. In addition, two patients harbored multiple
mtDNA deletions. One of the novel variants was
m.15933G >A in MTTT in a patient with ptosis, mild
muscle weakness, myalgia, mild dysphagia, psoriasis and
with RRF and COX-negative fibers in skeletal muscle. This
variant is situated at the base of the T stem of tRNAThr in
tRNA consensus position 49, which is highly conserved
among mammals, including its pair nucleotide at position
65 [35]. Nuclear mitochondrial DNA as a source of
m.15933G >A was excluded by whole mitochondrial gen-
ome amplification and subsequent sequencing. The inser-
tion m.15933_15934insG in the same position has been
reported in one subject (GenBank: JQ702629.1) [36]. This
insertion is not considered to be deleterious, because it
makes the preceding variable loop one base pair longer
but it retains the conserved m.15933G. On the other
hand, the m.15933G >A removes the highly conserved G
in the beginning of the T stem and decreases the length of
the T stem to four base pairs (Fig. 2). Another example of
a similar pair of a pathogenic mutation and a polymorphic
insertion is present in the T stem of MTTL2, where
m.12311 T > C is pathogenic and m.12311_12312insA is
polymorphic variant [35, 37, 38]. Altogether six confirmed
pathogenic mutations have been reported in MTTT [22,
23]. The symptoms of the patient, the conserved nature of
the nucleotide site and the predicted high probability in
favour of pathogenicity suggest that m.15933G >A is
pathogenic, but further functional studies will be needed
to discern the biochemical consequences of the mutation.
The patient with the novel m.15933G > A harboured
also the novel variant m.8743G > C (p.V73L, MTATP6).
This position holds a known polymorphism of
m.8743G > A (p.V73M, MTATP6), but the transversion
Table 1 Evolutionary conservation analysis of the novel





























Mammalian MTTT sequences covering the T-stem base pairs and the T-loop.
The nucleotide position m.15933 in consensus position 49 and its pair in
position 65 are shown in the superscripts and the nucleotides are underlined
Fig. 2 The m.15933G > A mutation in MTTT. a Invariable nucleotides among 135 mammal species in MTTT according to sequence alignment in
Mamit tRNA [24]. b Human polymorphisms and pathogenic mutations in MTTT. Polymorphisms are marked with white circles, black circles denote
confirmed pathogenic mutations and undetermined variants are marked with a white square ([24, 42])
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m.8743G > C has not been previously reported in data-
bases. This nucleotide position is variable and the amino
acid at this position is not evolutionarily conserved. We
consider this novel variant unlikely to be pathogenic.
The three rare variants included the insertion
m.7585_7586insT that was discovered in a patient with a
multi-organ phenotype. The m.7585_7586insT variant is
interesting, as it adds a nucleotide in between the contigu-
ous MTTD and MTCO2 genes and may interfere with
translation by one of three mechanisms. First, the MTTD
transcript could be one nucleotide longer thus
interrupting its proper function. Alternatively, the
m.7585_7586insT insertion may affect the translation of
MTCO2. The third possible mechanism entails that the
RNAase cleavage site in between MTTD and MTCO2 is
disrupted. However, m.7585_7586insT has previously been
discovered in four subjects belonging to haplotype H35,
three of whom are Finnish. Our patient belonged to
haplotype H1 suggesting that m.7585_7586insT has arisen
at least twice in this population. Additional studies are
needed to verify, if m.7585_7586insT indeed affects the
function of mitochondria. Unfortunately, only a few blood
samples were available from this family and no autopsy
had been performed on the proband after his death.
The frequency of rare nonsynonymous variants among
the 66 patients did not differ from that in 89
haplogroup-matched controls drawn from the popula-
tion [14]. Five out of the 47 nonsynonymous variants
were predicted to be pathogenic in effect. Four algo-
rithms were used including SNAP, SIFT BLink,
PolyPhen-2 and PMut. These algorithms have been
reported to accurately predict 76% of non-neutral vari-
ants, and SNAP is among the most accurate methods
for predicting damaging variants [39]. We assumed the
best candidates for pathogenic mutations to be those
that three out of four algorithms predicted to be patho-
genic. Three out of five predicted pathogenic variants
were haplogroup-associated and, indeed, we found these
variants in the same haplogroups as previously reported,
suggesting that they are haplogroup-associated polymor-
phisms. On the other hand, m.5095 T > C (p.I209T,
MTND2) has previously been reported in multiple hap-
logroups (B, C, T, A, U5a, R) [23], whereas we discov-
ered it in haplogroup H. This patient presented with
proximal muscle weakness and atrophy, orbicularis oculi
muscle weakness, myalgia and a large psoriasis-type
rash. Inflammatory changes were detected in muscle
histology. The true pathogenicity of m.5095 T > C re-
mains, however, unknown despite the high pathogenicity
prediction score, as this mutation has been discovered in
healthy individuals. Multiple mtDNA deletions were dis-
covered in two patients aged 33 and 42 years with sus-
pected mitochondrial disease. Multiple mtDNA
deletions do occur normally in the course of healthy
aging, but up to 48% of younger mitochondrial disease
patients with multiple deletions harbour POLG1 muta-
tions [40]. We found a heterozygous p.R722H allele in
one patient, while the other patient with multiple dele-
tions did not harbour any POLG1 mutations. The clin-
ical features of the patient with the heterozygous
p.R722H allele included progressive external ophthalmo-
plegia, diplopia, ptosis, mild exercise intolerance, and
numerous RRFs and COX negative fibers in skeletal
muscle. The p.R722H POLG1 allele has not been associ-
ated with disease in a heterozygous state, whereas in the
homozygous state it leads to progressive external
ophthalmoplegia, sensorineural hearing impairment, dia-
betes mellitus, dysphagia, a limb myopathy and dementia
[41]. Patient 22 with multiple deletions, but without
POLG1 mutations, also harboured a novel nonsynon-
ymous mtDNA mutation m.11322A > G (p. N188S,
MTND4) that was predicted to be neutral.
Conclusions
We determined the coding region mtDNA sequence of
66 Finnish patients with suspected mitochondrial dis-
ease. Among the 47 nonsynonymous variants, five were
predicted to be deleterious in effect by using four
Table 2 Nonsynonymous mtDNA variants predicted to be likely pathogenic
Variant Protein change Gene PolyPhen-2 (%)a SIFT Blinkb SNAPc Pmutd Haplogroup association Patient haplogroup
m.5095 T > C p.I209T MTND2 99.8 0 Pat/58% Pat/7 Multiple H2
m.8616G > T p.L30F MTATP6 99.9 0 Neutral/85% Pat/7 I1, M74 I1
m.10192C > T p.S45F MTND3 0 0.02 Pat/58% Pat/6 J1 J1
m.12135C > A p.S459Y MTND4 90.6 0 Pat/63% Pat/9 U8, B4 U8
m.14180 T > C p.Y165C MTND6 99.7 0.02 Pat/63% Pat/7 L2, T2, D4 H1
aPolyPhen-2 estimated probability of the variant being damaging: probabilities ~50% are classified as possibly damaging and probabilities >90% are classified as
probably damaging
bSIFT score ranges from 0 to 1. The amino acid substitution is predicted damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05
cSNAP assigns variants as neutral or non-neutral. An expected accuracy percent is given ranging from 50 to 100%, lower than 50% accurate predictions are
not reported
dPMut predicts a variant either pathogenic or neutral. A reliability index is given, ranging from 0 (most unreliable) to 9 (most reliable)
The algorithms used for prediction included PolyPhen-2, SNAP, SIFT BLink and PMut. Variants were considered to be likely pathogenic if at least three algorithms
predicted a damaging effect
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algorithms in parallel, but three of them were considered
haplogroup-associated polymorphisms. A likely patho-
genic novel mutation m.15933G > A (MTTT) was
discovered in patient with a suspected mitochondrial
disease. Sequencing of the mtDNA coding region is
recommended for patients presenting with symptoms of
a mitochondrial disorder but lacking the common
disease-causing mutations in mtDNA.
Abbreviations
COX: Cytochrome oxidase; CRS: The Cambridge reference sequence;
CSGE: Conformation sensitive gel electrophoresis; D-loop: Displacement loop,
non-coding mtDNA segment; HVSI: Hypervariable segment I;
MELAS: Mitochondrial encephalomyopathy, lactic acidosis with stroke-like ep-
isodes; MtDNA: Mitochondrial DNA; MTTT: Mitochondrial tRNA Threonine
gene; NARP: Neuropathy, ataxia and retinitis pigmentosa; nDNA: Nuclear
DNA; POLG1: Polymerase γ gene; RFLP: Restriction fragment length
polymorphism; RRF: Ragged red fiber
Acknowledgements
We greatly appreciate the technical assistance of Ms. Anja Heikkinen and Ms.
Pirjo Keränen.
Funding
This study was supported by grants from Academy of Finland (project
numbers 107174, 127764 and 266498), the Sigrid Juselius Foundation, the
Finnish Graduate School for Population Genetics, the Päivikki and Sakari
Sohlberg Foundation, The Alma and K.A. Snellman Foundation and the
University of Oulu, Finland.
Availability of data and materials
Patient mtDNA sequences are available in GenBank: KY496857-KY496890.
Authors’ contributions
RH, JU and KM designed the study. HKS, AV, LK and RH generated and
analysed the data. MK and JSM collected and analysed patient data. HKS and
KM wrote the paper with contributions from other authors. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The ethics committee of the University of Oulu has approved the study
protocol. All procedures performed in studies involving human participants
were in accordance with the ethical standards with the 1964 Helsinki
declaration and its later amendments. Informed consent was obtained from
all individual participants included in the study.
Author details
1Research Unit of Clinical Neuroscience, Neurology, University of Oulu, P.O.
Box 5000FI-90014 Oulu, Finland. 2Medical Research Center Oulu, Oulu
University Hospital and University of Oulu, P.O. Box 5000FI-90014 Oulu,
Finland. 3Department of Neurology, Oulu University Hospital, P.O. Box
20FI-90029 OYS Oulu, Finland. 4PEDEGO Research Unit, Pediatrics, University
of Oulu, P.O. Box 5000FI-90014 Oulu, Finland. 5Department of Pediatrics, Oulu
University Hospital, P.O. Box 23FI-90029 OYS Oulu, Finland. 6Department of
Clinical Genetics, Oulu University Hospital, P.O. Box 23FI-90029 OYS Oulu,
Finland. 7PEDEGO Research Unit, Clinical Genetics, University of Oulu, P.O.
Box 5000FI-90014 Oulu, Finland.
Received: 25 January 2016 Accepted: 3 February 2017
References
1. Chinnery PF, Elliott HR, Hudson G, Samuels DC, Relton CL. Epigenetics,
epidemiology and mitochondrial DNA diseases. Int J Epidemiol.
2012;41(1):177–87.
2. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C,
Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, Mcfarland R.
Prevalence of nuclear and mitochondrial DNA mutations related to adult
mitochondrial disease. Ann Neurol. 2015;77(5):753–9.
3. Ylikallio E, Suomalainen A. Mechanisms of mitochondrial diseases. Ann Med.
2012;44(1):41–59.
4. Breen MS, Kondrashov FA. Mitochondrial pathogenic mutations are
population-specific. Biol Direct. 2010;5:68.
5. Zhou X, Qian Y, Zhang J, Tong Y, Jiang P, Liang M, Dai X, Zhou H, Zhao F, Ji
Y, Mo JQ, Qu J, Guan MX. Leber’s hereditary optic neuropathy is associated
with the T3866C mutation in mitochondrial ND1 gene in three Han Chinese
families. Invest Ophthalmol Vis Sci. 2012;53(8):4586–94.
6. Cai W, Fu Q, Zhou X, Qu J, Tong Y, Guan MX. Mitochondrial variants may
influence the phenotypic manifestation of Leber’s hereditary optic
neuropathy-associated ND4 G11778A mutation. J Genet Genomics. 2008;
35(11):649–55.
7. Shu L, Zhang YM, Huang XX, Chen CY, Zhang XN. Complete mitochondrial
DNA sequence analysis in two southern Chinese pedigrees with Leber
hereditary optic neuropathy revealed secondary mutations along with the
primary mutation. Int J Ophthalmol. 2012;5(1):28–31.
8. Achilli A, Olivieri A, Pala M, Hooshiar Kashani B, Carossa V, Perego UA,
Gandini F, Santoro A, Battaglia V, Grugni V, Lancioni H, Sirolla C, Bonfigli AR,
Cormio A, Boemi M, Testa I, Semino O, Ceriello A, Spazzafumo L, Gadaleta
MN, Marra M, Testa R, Franceschi C, Torroni A. Mitochondrial DNA
backgrounds might modulate diabetes complications rather than T2DM as
a whole. Plos One. 2011;6(6):e21029.
9. Soini HK, Moilanen JS, Finnila S, Majamaa K. Mitochondrial DNA sequence
variation in Finnish patients with matrilineal diabetes mellitus. BMC Res
Notes. 2012;5(1):350.
10. Santoro A, Balbi V, Balducci E, Pirazzini C, Rosini F, Tavano F, Achilli A, Siviero
P, Minicuci N, Bellavista E, Mishto M, Salvioli S, Marchegiani F, Cardelli M,
Olivieri F, Nacmias B, Chiamenti AM, Benussi L, Ghidoni R, Rose G, Gabelli C,
Binetti G, Sorbi S, Crepaldi G, Passarino G, Torroni A, Franceschi C. Evidence
for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset
Alzheimer’s disease. Plos One. 2010;5(8):e12037.
11. Coskun P, Wyrembak J, Schriner SE, Chen HW, Marciniack C, Laferla F,
Wallace DC. A mitochondrial etiology of Alzheimer and Parkinson disease.
Biochim Biophys Acta. 2012;1820(5):553–64.
12. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E.
Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci.
2012;322(1–2):254–62.
13. Khusnutdinova E, Gilyazova I, Ruiz-Pesini E, Derbeneva O, Khusainova R,
Khidiyatova I, Magzhanov R, Wallace DC. A mitochondrial etiology of
neurodegenerative diseases: evidence from Parkinson’s disease. Ann N Y
Acad Sci. 2008;1147:1–20.
14. Finnilä S, Lehtonen MS, Majamaa K. Phylogenetic network for European
mtDNA. Am J Hum Genet. 2001;68(6):1475–84.
15. Meinilä M, Finnilä S, Majamaa K. Evidence for mtDNA admixture between
the Finns and the Saami. Hum Hered. 2001;52(3):160–70.
16. Torroni A, Huoponen K, Francalacci P, Petrozzi M, Morelli L, Scozzari R, Obinu D,
Savontaus ML, Wallace DC. Classification of European mtDNAs from an analysis
of three European populations. Genetics. 1996;144(4):1835–50.
17. Körkkö J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L. Conformation
sensitive gel electrophoresis for simple and accurate detection of
mutations: comparison with denaturing gradient gel electrophoresis and
nucleotide sequencing. Proc Natl Acad Sci U S A. 1998;95(4):1681–5.
18. Finnilä S, Hassinen IE, Ala-Kokko L, Majamaa K. Phylogenetic network of the
mtDNA haplogroup U in Northern Finland based on sequence analysis of
the complete coding region by conformation-sensitive gel electrophoresis.
Am J Hum Genet. 2000;66(3):1017–26.
19. Werle E, Schneider C, Renner M, Volker M, Fiehn W. Convenient single-step,
one tube purification of PCR products for direct sequencing. Nucleic Acids
Res. 1994;22(20):4354–5.
Soini et al. BMC Medical Genetics  (2017) 18:14 Page 7 of 8
20. Remes AM, Majamaa-Voltti K, Kärppä M, Moilanen JS, Uimonen S, Helander
H, Rusanen H, Salmela PI, Sorri M, Hassinen IE, Majamaa K. Prevalence of
large-scale mitochondrial DNA deletions in an adult Finnish population.
Neurology. 2005;64(6):976–81.
21. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell
N. Reanalysis and revision of the Cambridge reference sequence for human
mitochondrial DNA. Nat Genet. 1999;23(2):147.
22. Lott MT, Leipzig JN, Derbeneva O, Xie HM, Chalkia D, Sarmady M, Procaccio
V, Wallace DC. mtDNA Variation and Analysis Using MITOMAP and
MITOMASTER. Curr Protoc Bioinformatics. 2013;1(23):1–26.
23. Putz J, Dupuis B, Sissler M, Florentz C. Mamit-tRNA, a database of
mammalian mitochondrial tRNA primary and secondary structures. RNA.
2007;13(8):1184–90.
24. Tanaka M, Cabrera VM, Gonzalez AM, Larruga JM, Takeyasu T, Fuku N, Guo
LJ, Hirose R, Fujita Y, Kurata M, Shinoda K, Umetsu K, Yamada Y, Oshida Y,
Sato Y, Hattori N, Mizuno Y, Arai Y, Hirose N, Ohta S, Ogawa O, Tanaka Y,
Kawamori R, Shamoto-Nagai M, Maruyama W, Shimokata H, Suzuki R,
Shimodaira H. Mitochondrial genome variation in eastern Asia and the
peopling of Japan. Genome Res. 2004;14(10A):1832–50.
25. Niroula A, Vihinen M. PON-mt-tRNA: a multifactorial probability-based
method for classification of mitochondrial tRNA variations. Nucleic Acids
Res. 2016;44(5):2020–7.
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging
missense mutations. Nat Methods. 2010;7(4):248–9.
27. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome
Res. 2001;11(5):863–74.
28. Ferrer-Costa C, Orozco M, de la Cruz X. Sequence-based prediction of
pathological mutations. Proteins. 2004;57(4):811–9.
29. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M.
PMUT: a web-based tool for the annotation of pathological mutations on
proteins. Bioinformatics. 2005;21(14):3176–8.
30. Bromberg Y, Yachdav G, Rost B. SNAP predicts effect of mutations on
protein function. Bioinformatics. 2008;24(20):2397–8.
31. Claustres M, Kozich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K,
Oosterwijk C, Peterlin B, van Ravenswaaij-Arts C, Zimmermann U, Zuffardi O,
Hastings RJ, Barton DE, European Society of Human Genetics.
Recommendations for reporting results of diagnostic genetic testing
(biochemical, cytogenetic and molecular Genetic). Eur J Hum Genet.
2014;22(2):160–70.
32. Wallis Y, Payne S, Mcanulty C, Bodmer D, Sistermans E, Robertson K, Moore
D, Abbs S, Deans Z, Devereau A. Practice guidelines for the evaluation of
pathogenicity and the reporting of sequence variants in clinical molecular
genetics. Birmingham: Association for Clinical Genetic Science (ACGS);
2013. p. 1–16.
33. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated
software package for population genetics data analysis. Evol Bioinformatics
Online. 2007;1:47–50.
34. Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring
intraspecific phylogenies. Mol Biol Evol. 1999;16(1):37–48.
35. Vilmi T, Moilanen JS, Finnilä S, Majamaa K. Sequence variation in the tRNA
genes of human mitochondrial DNA. J Mol Evol. 2005;60(5):587–97.
36. Behar DM, van Oven M, Rosset S, Metspalu M, Loogvali EL, Silva NM, Kivisild
T, Torroni A, Villems R. A “Copernican” reassessment of the human
mitochondrial DNA tree from its root. Am J Hum Genet.
2012;90(4):675–84.
37. Herrnstadt C, Elson JL, Fahy E, Preston G, Turnbull DM, Anderson C, Ghosh
SS, Olefsky JM, Beal MF, Davis RE, Howell N. Reduced-median-network
analysis of complete mitochondrial DNA coding-region sequences for the
major African, Asian, and European haplogroups. Am J Hum Genet.
2002;70(5):1152–71.
38. van Oven M, Kayser M. Updated comprehensive phylogenetic tree of global
human mitochondrial DNA variation. Hum Mutat. 2009;30(2):E386–94.
39. da Hao C, Feng Y, Xiao R, Xiao PG. Non-neutral nonsynonymous single
nucleotide polymorphisms in human ABC transporters: the first comparison
of six prediction methods. Pharmacol Rep. 2011;63(4):924–34.
40. Ferreira M, Evangelista T, Almeida LS, Martins J, Macario MC, Martins E,
Moleirinho A, Azevedo L, Vilarinho L, Santorelli FM. Relative frequency of
known causes of multiple mtDNA deletions: two novel POLG mutations.
Neuromuscul Disord. 2011;21(7):483–8.
41. Komulainen T, Hinttala R, Kärppä M, Pajunen L, Finnilä S, Tuominen H,
Rantala H, Hassinen I, Majamaa K, Uusimaa J. POLG1 p.R722H mutation
associated with multiple mtDNA deletions and a neurological phenotype.
BMC Neurol. 2010;10:29.
42. Ruiz-Pesini E, Lott MT, Procaccio V, Poole JC, Brandon MC, Mishmar D, Yi C,
Kreuziger J, Baldi P, Wallace DC. An enhanced MITOMAP with a global
mtDNA mutational phylogeny. Nucleic Acids Res. 2007;35(Database issue):
D823–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Soini et al. BMC Medical Genetics  (2017) 18:14 Page 8 of 8
